Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
JUNB
REST API REST API
Homo sapiens
JUNB is differentially expressed in 316 experiments: 118 organism parts: lung, prostate, ... (116 more);, 174 disease states: normal, lung adenocarcinoma, ... (172 more);, 100 cell types 317 cell lines 58 compound treatments and 79 other conditions.
Orthologs F7B9Z5_CIOIN (Ciona intestinalis)   Junb (Rattus norvegicus)   junbl (Danio rerio)   Junb (Mus musculus)   junb (Danio rerio)   JUNB_BOVIN (Bos taurus)   Jra (Drosophila melanogaster)   junb (Xenopus laevis)   JUNB (Canis familiaris)   (Compare orthologs)
InterPro Term bZIP_1, bZIP_2, Leuzip_Jun, JNK, TF_bZIP
Gene Ontology Term DNA binding, protein binding, cellular process, regulation of transcription, DNA-dependent, double-stranded DNA binding, transcription corepressor activity, transcription from RNA polymerase II promoter, sequence-specific DNA binding, protein dimerization activity, response to cAMP, transcription coactivator activity, regulation of cell cycle, nucleus, response to drug, response to light stimulus, chromatin, regulation of transcription from RNA polymerase II promoter, response to mechanical stimulus, response to corticosterone stimulus, female pregnancy, response to cytokine stimulus, embryonic process involved in female pregnancy, in utero embryonic development, decidualization, response to progesterone stimulus, osteoblast differentiation, vasculogenesis, osteoblast proliferation, cellular response to calcium ion, positive regulation of cell differentiation, response to peptide hormone stimulus, cellular response to hormone stimulus, trophectodermal cell differentiation, labyrinthine layer blood vessel development, osteoclast differentiation, sequence-specific DNA binding transcription factor activity, response to organic cyclic compound, positive regulation of transcription from RNA polymerase II promoter during mitosis
UniProt Accession Q5U079, P17275
Search EB-eye ENSG00000171223
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
HCC1937
2
E-MTAB-37, E-MTAB-62
Daudi
2
E-MTAB-37, E-GEOD-96
HL-60
2
E-GEOD-96, E-GEOD-24147
MCF-10A
2
E-GEOD-14990, E-TABM-420
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MOLT4
2
E-MTAB-62, E-MTAB-37
311 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (50 experiments)

Factor Value U/D Experiments
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
2
E-TABM-145, E-TABM-130
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
fibroblast
2
E-GEOD-3204, E-GEOD-3920
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
94 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-TABM-15, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MEXP-2034, E-MTAB-62, E-GEOD-96, E-GEOD-7307
lung adenocarcinoma
1
3
E-MTAB-37, E-GEOD-2514, E-MTAB-62, E-MEXP-231
breast cancer
2
E-GEOD-22544, E-MTAB-62
chronic myelogenous leukemia
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
168 more value(s).


Compound treatment

studied in E-GEOD-2639, E-GEOD-5741, E-TABM-782, E-GEOD-697, E-GEOD-5824, ... (37 experiments)

Factor Value U/D Experiments
none
8
12
E-TABM-782, E-TABM-868, E-MEXP-1601, E-GEOD-4600, E-GEOD-5824, ... (20 experiments)
lipopolysaccharide
3
E-TABM-868, E-GEOD-3720, E-MEXP-1958
interferon-gamma + lipopolysaccharide
2
E-GEOD-5099, E-GEOD-7307
tumor necrosis factor
1
E-GEOD-2639
U0126
1
E-GEOD-697
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
52 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
47.81
1
E-TABM-325


Age at diagnosis
studied in E-GEOD-21653

Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-TABM-234, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-1323, E-MEXP-480, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, ... (11 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, E-TABM-868, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-GEOD-12773, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-4600, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-548, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-21164, E-GEOD-16797, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428, E-GEOD-12710 ... (5 experiments)

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16193, E-GEOD-16837, E-MEXP-973, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-6532, E-GEOD-4922 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.295 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM